Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?

Axe Cap view

Roche's Weight Loss Drug: A Threat to Eli Lilly and Novo Nordisk?

Roche’s enicepatide shows promise but may struggle to unseat market leaders in weight loss treatments.

Roche’s new weight loss candidate, enicepatide, posted a solid 22.5% weight reduction in its Phase 2 trial—results that rival Eli Lilly’s Zepbound and Novo Nordisk’s semaglutide. That’s impressive on paper and confirms Roche is serious about battling in both diabetes and weight loss markets. But Roche’s pipeline doesn’t run as deep as Eli Lilly’s or Novo Nordisk’s, which both have drugs advancing through late-stage trials and established market heft. For South African investors, this isn’t a call to abandon existing pharma plays but rather a reminder that diversification within healthcare is smart. Roche (RHHBY) might be a stable, lower-volatility holding compared to the headline-grabbing growth stories from Lilly (LLY) or Novo (NVO). Currency-wise, the rand (USD/ZAR) will remain a significant factor here—if the rand weakens, foreign-denominated drug developers could appear pricier, affecting local portfolio choices. If Roche’s enicepatide under-delivers in Phase 3 or the market shifts on regulatory risks, this view could flip quickly. this is just our opinion and not financial advice